Intus Bio has developed the Titan-1™ platform, a cutting-edge technology for microbiome analysis that surpasses traditional methods such as 16S and shotgun metagenomics. This proprietary platform utilizes a patented assay combined with advanced artificial intelligence (AI) tools to deliver high-resolution, strain-level data. Unlike conventional approaches that typically yield genus and species-level results, Titan-1™ can identify and track specific strains of bacteria, which are crucial for understanding their roles in health and disease. This capability allows for more precise biomarker discovery and drug response analysis, making it a valuable resource for pharmaceutical and academic collaborations.

The Titan-1™ platform operates on a unique methodology that generates a bacterial strain's composite "fingerprint" by analyzing multiple copies of the 16S-ITS-23S region. This innovative approach enables rapid and accurate identification of both known and novel strains without the need for whole-genome sequencing. Intus Bio's technology is designed to be high throughput and database independent, ensuring scalability and efficiency in microbiome research. By controlling every step of the process, from sample preparation to AI-driven analysis, Intus Bio sets itself apart in the field of microbiome discovery, providing actionable insights that can significantly impact therapeutic and diagnostic applications.

United States

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. 

The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Intus Bio

Company Details